Virax Biolabs Group Ltd. Class A (VRAX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Virax Biolabs Group Ltd. has partnered with French company Tebubio to distribute its ImmuneSelect portfolio across the European Union, Norway, and Switzerland. This collaboration aims to enhance the accessibility of ImmuneSelect products, which are crucial for researching adaptive immunity. The products, optimized for stimulating T cells, are intended for research use and not for diagnostic purposes.
For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.